Escherichia

• The NMRC has recently completed the in-patient stage of the campylobacter challenge clinical study.
• Headline results from the clinical trial are anticipated to be reported in H2 2024.
• The Phase 2 clinical trial is designed to evaluate the safety and protective efficacy of the new product manufactured by Immuron compared to a placebo in a controlled human infection model (CHIM).
• The inpatient challenge phase of the Travelan clinical study led by Principal Investigator Dr Mohamed Al-Ibrahim at the Pharmaron CPC FDA inspected Clinical Research Facility Inpatient Unit located in Baltimore, Maryland US, has been completed.

• The rod-shaped bacterium named Escherichia coli, better known as E. coli, is a very common microbe residing in your gut.
• For instance, drugs like penicillin fall into a class of antibiotics that target the outer defenses of the bacteria.
• We found that while E. coli succumbs to this attack, species like Vibrio or Klebsiella can tolerate it and survive.
• A one-size-fits-all approach may have worked in the past, but embracing the true diversity of microbes could help scientists better fight the rise of antibiotic resistance.

Scientific good of E. coli

• E. coli helped reveal that bacterial chromosomes are circular and that manipulating a specific enzyme can allow scientists to easily clone parts of the bacterial genome.
• E. coli also opened doors to using a type of bacterial viruses called phages as an alternative to antibiotics.
• Widely available knowledge about and methods to study E. coli led to its prominence in academic and commercial research and drug production.
• In 2015, nearly 30% of proteins used as treatments for a wide range of diseases like hepatitis C and multiple sclerosis were derived from E. coli.

Model organism drawbacks

• E. coli’s track record has solidified its place in the lab as a model organism.
• Model organisms are nonhuman species researchers use to study biology, with the expectation that the findings can be applied to other species like humans.
• However, model organisms have their drawbacks.

ESKAPE pathogens don’t include E. coli

• While some strains of E. coli can be deadly, they are not the only worrisome pathogens today.
• ESKAPE pathogens, a group of bacteria that are highly resistant to antibiotics, pose a massive global health threat because they can quickly evolve traits that allow them to evade immune systems and available treatments.
• Our lab is studying the unique traits that allow ESKAPE pathogens to survive antibiotics – traits we would not have known about if we used only E. coli as a model organism in our research.
• With the many basics of fundamental bacterial cell and molecular biology covered thanks to E. coli, it may be time for researchers to turn toward the new pathogens wreaking havoc on society.

• MONTREAL, Jan. 24, 2023 /PRNewswire/ - It is an absolute honor for Sani Sport to be a part of this medical study , which has now been formally published in Genes.
• As the pandemic came to a rise, the Weill Cornell Medical College sought out a solution on how to reduce bacteria and viruses within a wide range of medical equipment.
• The Sani Sport Supreme machine quickly became the focal point of their study.
• The Sani Sport Supreme is used throughout law enforcement, the military and professional sports to significantly reduce pathogens in their protective equipment.

• It also provides four different types of ice and can keep food fresh longer with LG's advanced cooling technologies.1
  The company's new 25.5-cu.
• The new model also brings a simple yet sophisticated aesthetic to the kitchen courtesy of LG's unique mirrored InstaView panel and flat door design.
• Bordered in sleek stainless steel, the mirror-coated glass of the seamless InstaView panel covers almost the entire right-hand door of the refrigerator.
• LG will be showcasing its latest home appliances, including the new InstaView French-Door refrigerator, at its exhibition booth (#15501, Las Vegas Convention Center) at CES 2023 in Las Vegas from January 5th-8th.